TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03043872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: IV infusions every 3 weeks for 12 weeks (4 cycles) and every 4 weeks thereafter until PD or other discontinuation criteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: IV infusions every 3 weeks for 12 weeks (4 cycles) and every 4 weeks thereafter until PD or other discontinuation criteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: IV infusions every 3 weeks for 12 weeks(4 cycles). An additional dose of tremelimumab will be administered in the week 16.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3
Study: NCT01105312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RNA analysis

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: microarray analysis

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enzyme-linked immunosorbent assay

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study: NCT00887705

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADL training
Description: The control group gets the standard rehabilitation programme which includes one hour ADL- training. The experimental group also gets the standard rehabilitation program, but instead of one hour they get an additional five hours ADL- training.
Study: NCT01602796

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School intervention
Description: The ITACA intervention is a cognitive and social-influences approach to prevent tobacco consumption. The intervention is integrated in the curricula of the school, also schools are reinforced to follow a smoke-free school and strictly follow legislation about smoking in schools. The community component include annual meeting with adolescents parents and parents and teachers intensive group for smoking cessation.
Study: NCT04224025

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise and respiratory therapy
Description: three weeks in-Hospital exercise Rehabilitation program with continuation at home (total 15 weeks).
Study: NCT00402727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (Avelox, BAY12-8039)
Description: Moxifloxacin (Avelox, BAY 12-8039) 400 mg intravenous (IV) once daily followed by Moxifloxacin 400 mg oral tablets once daily for a minimum of 7 days and a maximum of 21 days. Oral phase was not always mandatory.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid
Description: Piperacillin/Tacobactam 4.0/0.5 g (PIP/TAZ) administered intravenous three times daily followed by Amoxicillin/Clavulanic acid (AMC) oral tablets 875/125 mg twice daily for a minimum of 7 days and a maximum of 21 days. Oral phase not always mandatory.
Study: NCT05868538

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum calprotectin and IMA concentrations
Description: Serum calprotectin and IMA concentrations were compared among active BD cases, inactive BD cases and control subjects.

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum calprotectin and IMA concentrations
Description: Serum calprotectin and IMA concentrations were compared among active BD cases, inactive BD cases and control subjects.
Study: NCT03568578

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir 0.5 mg
Description: Patients in this group will be given Entecavir 0.5 mg a day for 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir 0.5 mg
Description: Patients in this group will be given Entecavir 0.5 mg a day for 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anluohuaxian Pill 12g
Description: Patients in this group will be given Entecavir 0.5 mg and Anluohuaxian Pill 12g a day for 2 years
Study: NCT00751140

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph Node Dissection
Description: The lymph nodes will be sent to pathology for review.
Study: NCT01345656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-8862
Description: Two 1.25 mg BAY94-8862 and 2 placebo tablets for duration of 4 weeks
Study: NCT00977574

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study: NCT01345656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-8862
Description: Four 1.25 mg BAY94-8862 tablets for duration of 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-8862
Description: One 10 mg BAY94-8862 tablet for duration of 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-8862
Description: Part B only: Four 1.25 mg BAY94-8862 tablets in the morning and four tablets in the evening for duration of 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets for duration of 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: Part B only: 25 mg spironolactone once daily with up-titration to 50 mg once daily starting at day 15, if serum potassium is less or equal to 4.8 mmol/L, for duration of 4 weeks
Study: NCT01628848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPM 962
Description: SPM 962 transdermal patch once a daily up to 36.0 mg/day
Study: NCT00977574

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV
Study: NCT01628848

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo transdermal patch
Study: NCT02864732

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation exercises

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation
Study: NCT01405898

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: beetroot juice
Description: Beetroot juice 4 weeks 250ml daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nitrate-free beetroot juice
Description: Nitrate-free beetroot juice 4 weeks 250ml daily
Study: NCT02141906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oncozene-DEB-TACE
Description: ONCOZENE microspheres are the newly available microspheres for DEB-TACE. It appears (based on the preliminary bench tests) that these microspheres may allow more efficient drug loading, and slow elution and equivalent vascular occlusion(12). In this pilot study, we aim to assess the safety of these microspheres when used for chemoembolization of unresectable hepatocellular carcinoma.
Study: NCT02985112

Intervention type: DEVICE
Intervention: FFR and IVUS-NIRS

Intervention type: DEVICE
Intervention: FFR and IVUS-NIRS
Study: NCT01839916

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04014218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhalation Sedation
Description: Inhalation Sedation by Administration of Sevoflurane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Sedation
Description: Intravenous Sedation by Administration of Propofol
Study: NCT04621058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: In case of Vitamin D levels \<30 or 40ng/ml patients will take vitamin D supplements.
Study: NCT06775990

Intervention type: OTHER
Intervention: Blood sample
Description: Children were not given any medication in the study. Peripheral blood samples from the children were collected, centrifuged and stored in the biochemistry laboratory in deep freezers at -80 degree celcius. From stored serum samples leptin, leptin receptor (LEPR), ghrelin, acylated ghrelin, deacylated ghrelin, ghrelin receptor (GHSR), kisspeptin (KISS1), kisspeptin receptor (KISS1R), preptin, Peroxisome proliferator-activated receptor gamma (PPAR γ), nod-like receptor pyrin domain-containing 3 (NLRP3), interleukin-18 (IL-18) levels were determined by ELISA in thirty obese and thirty healthy children.

Intervention type: OTHER
Intervention: Blood sample
Description: Children were not given any medication in the study. Peripheral blood samples from the children were collected, centrifuged and stored in the biochemistry laboratory in deep freezers at -80 degree celcius. From stored serum samples leptin, leptin receptor (LEPR), ghrelin, acylated ghrelin, deacylated ghrelin, ghrelin receptor (GHSR), kisspeptin (KISS1), kisspeptin receptor (KISS1R), preptin, Peroxisome proliferator-activated receptor gamma (PPAR γ), nod-like receptor pyrin domain-containing 3 (NLRP3), interleukin-18 (IL-18) levels were determined by ELISA in thirty obese and thirty healthy children.
Study: NCT04621058

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Placebo capsules exactly the same as the above, but without the active component.
Study: NCT04094961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Oral, administered four times per cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Oral, administered 14 times per cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral, fixed dose administered 8 times per cycle
Study: NCT03016091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: anti PD-L1
Study: NCT04531722

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative brain microdialysis
Description: Our current standard practice is to use a lateral approach through the middle temporal gyrus to place 3 depth electrodes targeting the hippocampus for intraoperative verification of pathological epileptiform activity prior to resection. Our research protocol will add one FDA approved electrode that has a central cannula for insertion of a microdialysis probe.
Study: NCT04371237

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression sleeve
Description: From foot to hip/groin on both legs with only 1 leg connected to pneumatic pump for 1 hour

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heat therapy
Description: Custom leg garment with one leg heated by circulating hot water approx 40 degrees C, the other leg approx 32 degrees C (thermoneutral) for 1 hour

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glycogen-depleting exercise session
Description: Prolonged intermittent high intensity running (LIST protocol)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glycogen-depleting exercise session
Description: Prolonged intermittent high intensity running (LIST protocol)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrient Intake (beverage)
Description: Post-exercise, all participants will receive a beverage containing 1.0 g/kg carbohydrate and 0.3 g/kg protein from the mixture of Gatorade Recover Protein Shake and Gatorade Thirst Quencher

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrient Intake (beverage)
Description: Post-exercise, all participants will receive a beverage containing 1.0 g/kg carbohydrate and 0.3 g/kg protein from the mixture of Gatorade Recover Protein Shake and Gatorade Thirst Quencher

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skeletal muscle biopsy
Description: Vastus lateralis muscle in the lower thigh will be obtained by the percutaneous needle technique
Study: NCT04710069

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POINT
Description: Patients randomized to the POINT program will be given preoperative counseling on adverse effects of opioids and expectations will be set that most patients do not require opioids for pain control after endocrine surgery, they will receive the info in writing afterwards as well. These patients will also be shown a short instructional video reiterating the counseling provided in the preoperative clinic visit. Information in the video will pertain to the expected pain after surgery, the over-the-counter options for pain control, the risks and side effects of using opioids, and reassurances that opioids may be prescribed at any time after discharge if pain is unmanageable. After the video, the patient will be provided with paperwork, requiring patient consent/signature to receive opioids if they opt into narcotic treatment. They will not be provided with a narcotic prescription if consent is not explicitly provided.
Study: NCT00507260

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Record
Description: A record of the amount and kind of food and drink you intake will be completed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Record
Description: A record of the amount and kind of food and drink you intake will be completed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Consults
Description: Meeting with a dietician consultant regarding issues related to food intake. Participants will also receive the results from the food records.
Study: NCT03284853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netarsudil/Latanoprost 0.02%/0.005%
Description: Topical sterile ophthalmic solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GANFORT®
Description: Topical sterile ophthalmic solution
Study: NCT04371237

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skeletal muscle biopsy
Description: Vastus lateralis muscle in the lower thigh will be obtained by the percutaneous needle technique
Study: NCT03863977

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: After the surgery, dexamethasone added to 1mg/kg of 0.5% bupivacaine in the TAP block.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: After the surgery, dexamethasone added to 1mg/kg of 0.5% bupivacaine in the TAP block.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: After the surgery,1mg/kg of 0.5% bupivacaine in the TAP block.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: After the surgery,1mg/kg of 0.5% bupivacaine in the TAP block.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: After the surgery,1mg/kg of 0.5% bupivacaine in the TAP block.
Study: NCT02790697

Intervention type: OTHER
Intervention: Indirect calorimetry
Description: Indirect calorimetry will be conducted using the new calorimeter and mixing chamber method using the mass spectrometer.
Study: NCT03642847

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13
Description: 13 valent Pneumococcal Conjugate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: multivalent pneumococcal conjugate formulation 1
Description: multivalent pneumococcal conjugate formulation 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: multivalent pneumococcal conjugate formulation 2
Description: multivalent pneumococcal conjugate formulation 2
Study: NCT01757951

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unimalleolar fixation
Description: Medial malleolus is fixed first and after that ankle mortise stability is assessed using external-rotation stress test. If talocrural joint is stable after fixation of medial malleolus, the patient is randomized to unimalleolar fixation group and no fixation of the lateral side is performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bimalleolar fixation
Description: Medial malleolus is fixed first and after that ankle mortise stability is assessed using external-rotation stress test. If talocrural joint is stable after fixation of medial malleolus, the patient is randomized to bimalleolar fixation group i.e. additional fixation of the lateral malleolus fracture is performed.
Study: NCT03437889

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Stimulus (Ice)
Description: The study procedure will be to use a cold stimulus (ice) to assess the subjects for hypesthesia the dermatomes of the lower abdomen between 10 and 30 minutes after the epidural catheter is inserted.
Study: NCT02774811

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prostaglandin analogue
Description: Topical therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective laser trabeculoplasy
Description: Laser therapy into drainage angle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laser
Study: NCT02086318

Intervention type: OTHER
Intervention: OvAge assessment
Description: Basal serum anti-Mullerian hormone (AMH), Follicle-stimulating hormone (FSH) and Estradiol (E2), antral follicle count (AFC), ovarian volume, Vascularization Index (VI), Flow Index (FI) and Vascularization Flow Index (VFI) will be measured in all women between day 1 and day 4 of menstrual cycle. Evaluation can be repeated after every kind of intervention regarding ovaries, both medical or surgical. Evaluation can be repeated also at interval of 3-6-12 months in order to study the modification of ovarian age when time passes.
Study: NCT02793739

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid filler injection
Description: Hyaluronic acid filler will be injected into the dorsal fingers at day 0 and at day 14 if a touch-up is necessary.
Study: NCT01475305

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received single intravenous (IV) dose of placebo matched to MEDI-557 on Day 1 and were inoculated with respiratory syncytial virus (RSV-A) (Memphis-37 strain) as intranasal drops on Day 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-557
Description: Participants received single IV dose of 30 milligram per kilogram (mg/kg) MEDI-557 on Day 1 and were inoculated with RSV-A (Memphis-37 strain) as intranasal drops on Day 3.
Study: NCT02385058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole
Description: Mebendazole 600 milligram (mg) tablet orally once starting on Day 1 and 21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole
Description: Mebendazole 600 milligram (mg) tablet orally once starting on Day 1 and 21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinfamide
Description: Quinfamide 200 mg tablet orally once starting on Day 1 and 21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinfamide
Description: Quinfamide 200 mg tablet orally once starting on Day 1 and 21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet orally once starting on Day 21.